50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
NASDAQ:OMER

Omeros - OMER Stock Forecast, Price & News

$3.32
-0.03 (-0.90%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.25
$3.51
50-Day Range
$3.32
$7.46
52-Week Range
$1.86
$14.61
Volume
362,872 shs
Average Volume
922,676 shs
Market Capitalization
$208.26 million
P/E Ratio
1.07
Dividend Yield
N/A
Price Target
$11.20

Omeros MarketRank™ Forecast

Analyst Rating
Hold
1.80 Rating Score
Upside/​Downside
208.7% Upside
$10.25 Price Target
Short Interest
Bearish
15.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.30
Upright™ Environmental Score
News Sentiment
1.33mentions of Omeros in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.06) to ($1.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

355th out of 1,071 stocks

Pharmaceutical Preparations Industry

150th out of 531 stocks

OMER stock logo

About Omeros (NASDAQ:OMER) Stock

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Receive OMER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter.

OMER Stock News Headlines

Omeros (NASDAQ: OMER)
Omeros: Managing An Investment After A Winning Trade
See More Headlines
Receive OMER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter.

OMER Company Calendar

Last Earnings
11/08/2021
Today
9/27/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:OMER
CUSIP
68214310
Employees
213
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$10.25
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+237.3%
Consensus Rating
Hold
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Net Income
$194.24 million
Pretax Margin
-575.85%

Debt

Sales & Book Value

Annual Sales
$73.81 million
Book Value
$0.38 per share

Miscellaneous

Free Float
56,269,000
Market Cap
$208.26 million
Optionable
Optionable
Beta
1.18

Social Links


Key Executives

  • Dr. Gregory A. Demopulos M.D. (Age 63)
    Co-Founder, Chairman, CEO & Pres
    Comp: $1.74M
  • Mr. Michael A. Jacobsen (Age 64)
    Chief Accounting Officer, VP of Fin. & Treasurer
    Comp: $505.32k
  • Mr. Peter B. Cancelmo J.D. (Age 43)
    VP, Gen. Counsel & Corp. Sec.
    Comp: $478.19k
  • Dr. Pamela Pierce Palmer M.D. (Age 59)
    Ph.D., Co-Founder
  • Dr. George A. Gaitanaris M.D. (Age 65)
    Ph.D., Chief Scientific Officer & VP of Science
  • Mr. Peter W. Williams (Age 54)
    VP of HR
  • Dr. J. Steven Whitaker J.D. (Age 66)
    M.D., VP of Clinical Devel. & Chief Medical Officer
  • Dr. Catherine A. Melfi Ph.D. (Age 63)
    Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
  • Ms. Nadia Dac (Age 52)
    VP & Chief Commercial Officer













OMER Stock - Frequently Asked Questions

Should I buy or sell Omeros stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares.
View OMER analyst ratings
or view top-rated stocks.

What is Omeros' stock price forecast for 2022?

5 equities research analysts have issued 1-year target prices for Omeros' shares. Their OMER share price forecasts range from $4.00 to $20.00. On average, they expect the company's stock price to reach $10.25 in the next twelve months. This suggests a possible upside of 208.7% from the stock's current price.
View analysts price targets for OMER
or view top-rated stocks among Wall Street analysts.

How have OMER shares performed in 2022?

Omeros' stock was trading at $6.43 at the beginning of the year. Since then, OMER shares have decreased by 48.4% and is now trading at $3.32.
View the best growth stocks for 2022 here
.

When is Omeros' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our OMER earnings forecast
.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) posted its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. The biopharmaceutical company earned $30 million during the quarter, compared to analyst estimates of $29.31 million. During the same quarter in the previous year, the business posted ($0.39) earnings per share.

What is Gregory A. Demopulos' approval rating as Omeros' CEO?

17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Omeros own?
What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Who are Omeros' major shareholders?

Omeros' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.95%), UBS Group AG (1.08%), Renaissance Technologies LLC (0.86%), State Street Corp (0.37%), Northern Trust Corp (0.24%) and Occudo Quantitative Strategies LP (0.23%). Insiders that own company stock include Gregory A Md Demopulos, Michael A Jacobsen and Thomas J Cable.
View institutional ownership trends
.

How do I buy shares of Omeros?

Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $3.32.

How much money does Omeros make?

Omeros (NASDAQ:OMER) has a market capitalization of $208.26 million and generates $73.81 million in revenue each year. The biopharmaceutical company earns $194.24 million in net income (profit) each year or $3.10 on an earnings per share basis.

How many employees does Omeros have?

The company employs 213 workers across the globe.

Does Omeros have any subsidiaries?
The following companies are subsidiares of Omeros: Nura.
Read More
How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The official website for the company is www.omeros.com. The biopharmaceutical company can be reached via phone at (206) 676-5000 or via fax at 206-676-5005.

This page (NASDAQ:OMER) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.